Objective: To explore the genes and mechanisms in colorectal cancer and adjacent tissues at different distances by bioinformatics analysis. Methods: Eukaryotic mRNA was sequenced by Illumina Novaseq 6000 sequencing platform. Results: Differential expression analysis showed that there were 28 000 differentially expressed genes in the upper margin group of colorectal cancer, of which 11 735 were up-regulated and 16 265 were down-regulated. There were 32 438 differentially expressed genes in the lower margin group of colorectal cancer, of which 11 477 were up-regulated and 20 961 were down-regulated. The differentially expressed genes IGF2BP1, ADAM12, CDON, AKAP6, IGSF9B, LONR2 and KCNB1 were found to be down-regulated in colorectal cancer tissues and adjacent tissues at different distances. Functional annotation analysis of differential genes showed that differential genes were mainly involved in cellular processes, and the pathways involved were mainly metabolism, signal transduction and immune system. In terms of pathogenesis, it mainly exists in cancer, nervous system diseases and gastrointestinal system diseases. Differential gene enrichment analysis showed that differential genes were mainly in cardiac conduction, collagen fiber tissue, collagen decomposition process, etc., and the enriched pathways were mainly human papillomavirus infection pathway and P13K-Akt signaling pathway. Conclusion: The expression of differential genes IGF2BP1, ADAM12, CDON, AKAP6, IGSF9 B, LONR2 and KCNB1 is down-regulated in colorectal cancer tissues and adjacent tissues at different distances. Differential genes exist in cells and are mainly involved in metabolic pathways, signal transduction pathways, and immune system pathways. The pathogenesis mainly exists in cancer, nervous system diseases and gastrointestinal system diseases.
LIU Guofang
,
ZHENG Liansheng
,
TANG Bofu
,
SHAO Guo
. The differential gene expression and mechanism of colorectal cancer and adjacent tissues at different distances based on bioinformatics analysis[J]. Journal of Baotou Medical College, 2025
, 41(1)
: 1
-8
.
DOI: 10.16833/j.cnki.jbmc.2025.01.001
[1] Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10): 101174.
[2] Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3): 233-254.
[3] Lauby-Secretan B, Vilahur N, Bianchini F, et al. The IARC perspective on colorectal cancer screening[J]. N Engl J Med, 2018, 378(18): 1734-1740.
[4] Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death[J]. N Engl J Med, 2022, 387(17): 1547-1556.
[5] Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development[J]. N Engl J Med, 1988, 319(9): 525-532.
[6] Thanikachalam K, Khan G. Colorectal cancer and nutrition[J]. Nutrients, 2019, 11(1): 164.
[7] Shinji S, Yamada T, Matsuda A, et al. Recent advances in the treatment of colorectal cancer: a review[J]. J Nippon Med Sch, 2022, 89(3): 246-254.
[8] Chakedis J, Schmidt CR. Surgical treatment of metastatic colorectal cancer[J]. Surg Oncol Clin N Am, 2018, 27(2): 377-399.
[9] Itatani Y, Kawada K, Sakai Y. Treatment of elderly patients with colorectal cancer[J]. Biomed Res Int, 2018, 2018: 2176056.
[10] Chen HM, Lin CC, Chen WS, et al. Insulin-Like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a prognostic biomarker and associated with chemotherapy responsiveness in colorectal cancer[J]. Int J Mol Sci, 2021, 22(13): 6940.
[11] Liu Y, Guo Q, Yang H, et al. Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment[J]. ACS Cent Sci, 2022, 8(8): 1102-1115.
[12] Huang Z, Lai H, Liao J, et al. Upregulation of ADAM12 is associated with a poor survival and immune cell infiltration in colon adenocarcinoma[J]. Front Oncol, 2021, 11: 729230.
[13] Uko NE, Güner OF, Matesic DF, et al. Akt pathway inhibitors[J]. Curr Top Med Chem, 2020, 20(10): 883-900.
[14] Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment[J]. Annu Rev Med, 2016, 67: 11-28.
[15] Chen H, Zhou L, Wu X, et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer [J]. Front Biosci (Landmark Ed), 2016, 21(5): 1084-1091.
[16] Zhu K, Wu Y, He P, et al. PI3K/AKT/mTOR-Targeted therapy for breast cancer[J]. Cells, 2022, 11(16): 2508.
[17] Zhou LA, Liu TB, Lü HN. Geraniin inhibits proliferation and induces apoptosis through inhibition of phosphatidylinositol 3-kinase/Akt pathway in human colorectal cancer in vitro and in vivo[J]. Anticancer Drugs, 2020, 31(6): 575-582.
[18] He Z, Xu Y, Rao Z, et al. The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine[J]. Sci Total Environ, 2024, 912: 169604.
